Esperion Therapeutics, Inc. (ESPR):企業概要、財務及び戦略的SWOT分析

◆英語タイトル:Esperion Therapeutics, Inc. (ESPR) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH185154FSA
◆発行会社(調査会社):GlobalData
◆発行日:2015年1月9日
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD300 ⇒換算¥33,900見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD600 ⇒換算¥67,800見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD900 ⇒換算¥101,700見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary

Esperion Therapeutics, Inc. (Esperion) is a biotechnology company. The company develops and commercializes oral, small molecule therapies for the treatment of patients with low-density lipoprotein cholesterol and other cardiometabolic risk factors. Esperion’s products include ETC-1002, ESP41091, 4WF, and HDL Mimetics. Its ETC-1002 is an oral drug for patients who have/are at risk for developing, cardiovascular and metabolic diseases. The company’s second generation compounds impacts lipid and carbohydrate metabolism and inflammation; and HDL mimetic therapies are designed to rapidly eliminate cholesterol and other lipids from the arterial wall and related tissues. The company operates as a subsidiary of Pfizer Inc. Esperion is headquartered in Plymouth, Michigan, the US.

Esperion Therapeutics, Inc. Key Recent Developments

Dec 23, 2013: Esperion Therapeutics Added to the NASDAQ Biotechnology Index
Nov 06, 2013: Esperion Therapeutics Reports Third Quarter 2013 Financial Results
Nov 05, 2013: Esperion Therapeutics to Present at Credit Suisse Healthcare Conference
Sep 24, 2013: Esperion Therapeutics to Present at BioCentury Newsmakers in the Biotech Industry Conference
Sep 10, 2013: Esperion Therapeutics to Present at Stifel Nicolaus 2013 Healthcare Conference

This comprehensive SWOT profile of Esperion Therapeutics, Inc. provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Esperion Therapeutics, Inc. including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

【レポートの目次】

Table of Contents

Section 1 – About the Company

Esperion Therapeutics, Inc. – Key Information
Esperion Therapeutics, Inc. – Overview
Esperion Therapeutics, Inc. – Key Employees
Esperion Therapeutics, Inc. – Key Employee Biographies
Esperion Therapeutics, Inc. – Key Operational Heads
Esperion Therapeutics, Inc. – Major Products and Services
Esperion Therapeutics, Inc. – History
Esperion Therapeutics, Inc. – Company Statement
Esperion Therapeutics, Inc. – Locations And Subsidiaries
Esperion Therapeutics, Inc. – Key Manufacturing facilities
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

Esperion Therapeutics, Inc. – Business Description
Esperion Therapeutics, Inc. – Corporate Strategy
Esperion Therapeutics, Inc. – SWOT Analysis
SWOT Analysis – Overview
Esperion Therapeutics, Inc. – Strengths
Esperion Therapeutics, Inc. – Weaknesses
Esperion Therapeutics, Inc. – Opportunities
Esperion Therapeutics, Inc. – Threats
Esperion Therapeutics, Inc. – Key Competitors

Section 3 – Company Financial Performance Charts

Esperion Therapeutics, Inc. – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts

Section 4 – Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Note*: Some sections may be missing if data is unavailable for the company

List of Tables

Esperion Therapeutics, Inc., Key Information
Esperion Therapeutics, Inc., Key Ratios
Esperion Therapeutics, Inc., Share Data
Esperion Therapeutics, Inc., Major Products and Services
Esperion Therapeutics, Inc., History
Esperion Therapeutics, Inc., Key Employees
Esperion Therapeutics, Inc., Key Employee Biographies
Esperion Therapeutics, Inc., Key Operational Heads
Esperion Therapeutics, Inc., Other Locations
Esperion Therapeutics, Inc., Subsidiaries
Esperion Therapeutics, Inc., Key Manufacturing facilities
Esperion Therapeutics, Inc., Key Competitors
Esperion Therapeutics, Inc., SWOT Analysis
Esperion Therapeutics, Inc., Ratios based on current share price
Esperion Therapeutics, Inc., Annual Ratios
Esperion Therapeutics, Inc., Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures

Esperion Therapeutics, Inc., Performance Chart
Esperion Therapeutics, Inc., Ratio Charts

★海外企業調査レポート[Esperion Therapeutics, Inc. (ESPR):企業概要、財務及び戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • University Hospitals:企業のM&A・提携動向(医療分野)
    Summary University Hospitals is a healthcare service provider that offers patient-centered medical care and education services. The hospitals’ services include abdominal imaging, acupuncture, addiction recovery, advanced heart failure and transplant, bariatric surgery, behavioral pediatrics and psyc …
  • Peab AB:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Peab AB Mergers and Acquisition …
  • TOLMAR Inc.(製薬・医療分野):企業M&A動向
    Summary TOLMAR Inc. (TOLMAR) is a pharmaceutical company. The company develops, manufactures and markets generic pharmaceutical products. Its products include mometasone furoate, betamethasone diproprionate, fluticasone propionate, mometasone furoate, metronidazole, lidocaine, prilocaine, erythromyc …
  • AbbVie Inc. (ABBV):企業のM&A・提携動向(医療機器分野)
    Summary AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company that carries out the research, development, manufacture and commercialization of advanced therapies to treat complex and serious diseases. The company’s products are used to treat Crohn's disease, cystic fibrosis complication …
  • Yeo Hiap Seng Limited:企業の戦略・SWOT・財務分析
    SummaryYeo Hiap Seng Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key F …
  • Wright Medical Group NV (WMGI):企業のM&A・提携動向(医療機器分野)
    Summary Wright Medical Group NV (Wright) is an international orthopedic medical device company with focus on extremity and biologic solutions. The company designs, manufactures and markets reconstructive joint devices including extremity implants for the shoulder, elbow, foot, ankle and hand; foot a …
  • BioLineRx Ltd.:企業のM&A・提携・投資分析
    BioLineRx Ltd. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's BioLineRx Ltd. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestmen …
  • Biogen Inc (BIIB)-製薬・医療分野:企業M&A・提携分析
    Summary Biogen Inc (Biogen) is a global biotechnology company that manufactures and markets drugs for the treatment of neurodegenerative diseases and rare and autoimmune disorders. Its marketed products include Avonex (interferon beta-1a), Tysabri (natalizumab), Tecfidera (dimethyl fumarate), Zinbry …
  • United BioSource Corp-製薬・医療分野:企業M&A・提携分析
    Summary United BioSource Corp (UBC), a subsidiary of Express Scripts Holding Company is a provider of pharmaceutical support services. The company offers medicines and medical products. Its services comprise clinical development and late stage research, risk management and pharmacovigilance, nursing …
  • PT Energi Mega Persada Tbk. (ENRG):企業概要、財務及び戦略的SWOT分析
    Summary PT Energi Mega Persada Tbk. (EMP) is an independent upstream oil and gas company. The company acquires, explores, develops and produces oil and gas from its assets. Its products include crude oil and natural gas. EMP’s supply chain managements include procurement of goods and services, inven …
  • Sutter Health:企業のM&A・提携動向(医療分野)
    Summary Sutter Health (Sutter Health) is a non-profit healthcare service provider, which provides health care service through its hospitals, ambulatory surgery centers, cardiac centers, cancer centers, rehabilitation centers and others. It serves communities across Northern California- in the San Fr …
  • 20 Microns Limited (20MICRONS):企業概要、財務及び戦略的SWOT分析
    Summary 20 Microns Limited (20 Microns) is a chemical company. The company produces and markets white minerals in the field of functional fillers, extenders and specialty chemicals. It operates through its product segments such as micronized minerals and specialty chemicals. 20 Microns’ products por …
  • Charter Hall Group:企業の戦略・SWOT・財務分析
    SummaryCharter Hall Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Find …
  • Arabian Shield Cooperative Insurance Company (8070):企業概要およびSWOT分析
    This report is a crucial resource for industry executives and anyone looking to access key information about "Arabian Shield Cooperative Insurance Company" The report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format …
  • Infratil Limited (IFT):企業のM&A・提携動向(エネルギー分野)
    Summary Infratil Limited (Infratil) is an investment company that provides energy, transportation and infrastructure services. The company’s projects include trustpower, lumo energy, infratil energy Australia, direct connect, Perth energy, Z energy, Wellington Airport, NZ bus, snapper, infratil prop …
  • Oncodesign SA (ALONC):企業財務及び戦略的SWOT分析
    Summary Oncodesign SA (Oncodesign) is a biotechnology company that offers drug discovery and pharmacological evaluation services for cancer. The company offers a wide range of products and services for the validation, assessment, targeting and diagnostic linking of anti-cancer therapies based on its …
  • RedHill Biopharma Ltd. (RDHL):企業の財務及び戦略的SWOT分析
    Summary RedHill Biopharma Ltd. (RedHill) is a biopharmaceutical company. It intends to acquire and develop late clinical-stage, proprietary drugs for the treatment of gastrointestinal and inflammatory conditions. The company’s product pipeline includes a heat shock protein 27 inhibitor in Phase I/II …
  • Galera Therapeutics Inc-製薬・医療分野:企業M&A・提携分析
    Summary Galera Therapeutics Inc (Galera Therapeutics) is a clinical stage biotechnology company that discovers and develops novel cancer treatments. The company also concentrates on the prevention of radiation-induced toxicity including mucositis and the treatment of cancer. Its GC4419 is a selectiv …
  • Ma San Group Corporation:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Ma San Group Corporation Merger …
  • Shin Poong Pharm(製薬・医療分野):企業M&A動向
    Summary Shin Poong Pharm Co., Ltd. (Shin Poong) is a pharmaceutical company. The company develops, markets, and distributes pharmaceutical products for various diseases. Its products include antibiotics, amino acids, gingival agents, antitussives and expectorants, antihistamines, thrombolytics, anti …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆